BSE: 532878 | NSE: ALPA | Pharmaceuticals & Drugs | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Alpa Laboratories Ltd is a below average quality company.
The key valuation ratios of Alpa Laboratories Ltd's currently when compared to its past seem to suggest it is in the Overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Alpa Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -3.6% | 0.5% | 7.2% | 7.2% | 5% | 2.3% | 4.6% | 4.8% | 6.2% | 6.4% | - |
| Value Creation Index ⓘ | -1.3 | -1.0 | -0.5 | -0.5 | -0.7 | -0.8 | -0.7 | -0.7 | -0.6 | -0.5 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 56.7 | 57.4 | 53.5 | 63.4 | 62.3 | 78 | 86 | 97.6 | 112 | 93 | 114 |
| Sales YoY Gr. | - | 1.2% | -6.8% | 18.5% | -1.8% | 25.2% | 10.2% | 13.5% | 15.1% | -17.2% | - |
| Adj EPS ⓘ | -2.6 | -0.3 | 3.5 | 3.3 | 2.2 | 1 | 2.3 | 2.6 | 3.7 | 4.2 | 8.5 |
| YoY Gr. | - | NA | NA | -5.7% | -33.1% | -55.9% | 135.7% | 10.8% | 43.8% | 15.2% | - |
| BVPS (₹) ⓘ | 42 | 41.1 | 44.8 | 46.8 | 49.1 | 50.4 | 52.4 | 55.9 | 62.6 | 68.7 | 75 |
| Adj Net Profit ⓘ | -5.5 | -0.7 | 7.4 | 7 | 4.7 | 2.1 | 4.9 | 5.4 | 7.7 | 8.9 | 18 |
| Cash Flow from Ops. ⓘ | 8.1 | -1.8 | -24.8 | -8.1 | -7.3 | -0.7 | 17.7 | -1.5 | 2.2 | 8.8 | - |
| Debt/CF from Ops. ⓘ | 2.9 | -15.6 | -1 | -1.3 | -0.8 | -2.5 | 0 | -0.1 | 2.7 | 0.3 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 5.6% | 8.3% | 2.6% | -17.2% | ||||
| Adj EPS ⓘ | NA | 13.8% | 22.4% | 15.2% | ||||
| BVPSⓘ | 5.6% | 7% | 9.5% | 9.8% | ||||
| Share Price | 26.5% | 30% | 11.9% | 54% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -6 | -0.8 | 8.2 | 7.3 | 4.6 | 2 | 4.5 | 4.7 | 6.2 | 6.5 | 11.9 |
| Op. Profit Mgn % ⓘ | 10 | 4.8 | 11.7 | 11.2 | 6.7 | 1.6 | 6.9 | 8.9 | 9.5 | 8.7 | 12.2 |
| Net Profit Mgn % ⓘ | -9.7 | -1.2 | 13.9 | 11 | 7.5 | 2.7 | 5.7 | 5.5 | 6.9 | 9.6 | 15.7 |
| Debt to Equity ⓘ | 0.3 | 0.3 | 0.3 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | - |
| Working Cap Days ⓘ | 263 | 249 | 403 | 432 | 356 | 280 | 238 | 222 | 224 | 277 | 233 |
| Cash Conv. Cycle ⓘ | 138 | 128 | 146 | 147 | 148 | 126 | 106 | 82 | 97 | 153 | 182 |
Return on Equity has increased versus last 3 years average to 11.90%
Net Profit is growing at healthy rate in last 3 years 22.44%
Sales growth is good in last 4 quarters at 41.75%
Sales growth has been subdued in last 3 years 2.64%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 8.5 | 8.6 |
| TTM Sales (₹ Cr.) | 114 | 114 |
| BVPS (₹.) ⓘ | 75 | 70.3 |
| Reserves (₹ Cr.) ⓘ | 137 | 127 |
| P/BV ⓘ | 1.27 | 1.35 |
| PE ⓘ | 11.14 | 11.11 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 55.10 / 115.00 |
| All Time Low / High (₹) | 5.50 / 115.00 |
| Market Cap (₹ Cr.) | 200 |
| Equity (₹ Cr.) | 21 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 47.6 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 57 | 57 | 54 | 63 | 62 | 78 | 86 | 98 | 112 | 93 |
| Operating Expenses ⓘ | 51 | 55 | 47 | 56 | 58 | 77 | 83 | 90 | 102 | 85 |
| Manufacturing Costs | 5 | 4 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 |
| Material Costs | 32 | 36 | 28 | 36 | 36 | 49 | 51 | 59 | 70 | 55 |
| Employee Cost | 8 | 8 | 7 | 9 | 10 | 12 | 12 | 12 | 12 | 12 |
| Other Costs ⓘ | 6 | 7 | 9 | 8 | 9 | 12 | 15 | 13 | 14 | 11 |
| Operating Profit ⓘ | 6 | 3 | 6 | 7 | 4 | 1 | 3 | 8 | 11 | 8 |
| Operating Profit Margin (%) | 10.0% | 4.8% | 11.7% | 11.2% | 6.3% | 1.6% | 4.0% | 7.9% | 9.5% | 8.7% |
| Other Income ⓘ | 1 | 3 | 7 | 7 | 5 | 5 | 3 | 4 | 11 | 9 |
| Interest ⓘ | 2 | 2 | 1 | 2 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation ⓘ | 9 | 6 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 |
| Exceptional Items ⓘ | 0 | -1 | 0 | -2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax ⓘ | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 |
| Tax ⓘ | 0 | -1 | 3 | 3 | 2 | 2 | 1 | 4 | 5 | 3 |
| Profit After Tax | -5 | -1 | 8 | 6 | 5 | 3 | 4 | 7 | 14 | 13 |
| PAT Margin (%) | -9.1% | -2.4% | 14.5% | 9.4% | 7.7% | 3.8% | 4.7% | 7.4% | 12.6% | 13.6% |
| Adjusted EPS (₹) | -2.5 | -0.7 | 3.7 | 2.9 | 2.3 | 1.4 | 1.9 | 3.5 | 6.7 | 6.0 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 88 | 87 | 94 | 98 | 103 | 106 | 110 | 118 | 132 | 145 |
| Share Capital ⓘ | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 | 21 |
| Reserves ⓘ | 67 | 66 | 73 | 77 | 82 | 85 | 89 | 96 | 111 | 123 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 20 | 29 | 24 | 11 | 6 | 1 | 0 | 0 | 4 | 1 |
| Long Term Debt | 4 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 | 1 |
| Short Term Debt | 16 | 29 | 24 | 10 | 5 | 1 | 0 | 0 | 2 | 0 |
| Trade Payables | 11 | 9 | 19 | 14 | 13 | 13 | 14 | 25 | 15 | 15 |
| Others Liabilities ⓘ | 8 | 4 | 10 | 5 | 4 | 8 | 6 | 8 | 14 | 17 |
| Total Liabilities ⓘ | 127 | 128 | 147 | 128 | 126 | 129 | 130 | 150 | 165 | 178 |
Fixed Assets | ||||||||||
| Gross Block | 102 | 24 | 25 | 26 | 28 | 29 | 30 | 31 | 34 | 33 |
| Accumulated Depreciation | 29 | 19 | 20 | 21 | 22 | 23 | 24 | 23 | 25 | 26 |
| Net Fixed Assetsⓘ | 73 | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 9 | 7 |
| CWIP ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 |
| Investmentsⓘ | 0 | 10 | 22 | 23 | 41 | 59 | 68 | 62 | 86 | 90 |
| Inventories | 13 | 8 | 15 | 13 | 14 | 14 | 13 | 17 | 15 | 13 |
| Trade Receivables | 20 | 24 | 34 | 29 | 25 | 30 | 25 | 35 | 38 | 47 |
| Cash Equivalents | 10 | 72 | 35 | 36 | 21 | 1 | 6 | 10 | 1 | 9 |
| Others Assetsⓘ | 10 | 9 | 36 | 22 | 18 | 19 | 12 | 17 | 15 | 13 |
| Total Assets ⓘ | 127 | 128 | 147 | 128 | 126 | 129 | 130 | 150 | 165 | 178 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | 8 | -2 | -25 | -8 | -7 | -1 | 18 | -1 | 2 | 9 |
| PBT ⓘ | -5 | -3 | 11 | 9 | 7 | 5 | 5 | 11 | 20 | 16 |
| Adjustment ⓘ | 12 | 6 | -1 | -3 | -1 | -1 | 4 | 1 | -8 | -2 |
| Changes in Working Capital ⓘ | 1 | -7 | -31 | -11 | -11 | -2 | 10 | -10 | -6 | -1 |
| Tax Paid ⓘ | 0 | 1 | -3 | -3 | -2 | -2 | -1 | -3 | -4 | -3 |
| Cash Flow From Investing Activity ⓘ | -2 | 37 | -7 | 1 | -16 | -15 | -11 | 6 | -16 | 2 |
| Capex | -2 | -1 | 0 | -1 | -2 | -1 | -3 | -3 | -2 | -1 |
| Net Investments | 0 | -10 | -12 | -3 | -18 | -12 | -12 | 8 | -15 | 0 |
| Others ⓘ | 0 | 49 | 6 | 6 | 4 | -2 | 3 | 1 | 2 | 4 |
| Cash Flow From Financing Activityⓘ | 4 | 7 | -6 | -2 | 4 | -5 | -1 | 0 | 5 | -3 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | -2 | -4 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | -1 |
| Interest Paid ⓘ | -2 | -2 | -1 | -2 | -1 | -1 | 0 | 0 | 0 | 0 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 8 | 13 | -4 | -1 | 5 | -4 | -1 | 0 | 4 | -2 |
| Net Cash Flow ⓘ | 10 | 42 | -37 | -9 | -19 | -20 | 5 | 4 | -8 | 7 |
| PARTICULARS | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -5.67 | -1.6 | 8.56 | 6.21 | 4.72 | 2.82 | 3.77 | 6.38 | 11.34 | 9.14 |
| ROCE (%) | -2.55 | -0.89 | 10.34 | 9.5 | 6.98 | 4.78 | 4.83 | 9.54 | 15.54 | 11.35 |
| Asset Turnover Ratio | 0.48 | 0.48 | 0.42 | 0.46 | 0.49 | 0.61 | 0.66 | 0.7 | 0.71 | 0.54 |
| PAT to CFO Conversion(x) | N/A | N/A | -3.13 | -1.33 | -1.4 | -0.33 | 4.5 | -0.14 | 0.14 | 0.69 | Working Capital Days |
| Receivable Days | 119 | 132 | 187 | 183 | 160 | 129 | 115 | 112 | 119 | 166 |
| Inventory Days | 79 | 61 | 72 | 81 | 78 | 65 | 56 | 54 | 52 | 55 |
| Payable Days | 109 | 99 | 181 | 164 | 136 | 97 | 96 | 118 | 104 | 99 |
Incorporated as Alpa Laboratories Private Limited on March 18, 1988 under the Companies Act, 1956 and converted to public limited company on September 3, 1998 with the name of Alpa Laboratories Limited. The company has been listed on the Bombay Stock Exchange and the National Stock Exchange since August 6, 2007.
Alpa Laboratories Limited is a WHO-GMP and ISO 9001:2000 certified company located at Pigdamber, about 15 kilometers from the city of Indore in Central India. The company has been manufacturing Pharmaceutical Finished Dosage Forms since 1967. With its focus on quality, the company has earned tremendous faith and confidence of its associates.
The manufacturing facility is less than 20 kilometers from the center of the city of Indore in Central India and is spread over 1.20 acres. The facility has dedicated manufacturing areas for different Finished Dosage Forms (FDFs) including liquid injections, dry injections, tablets, capsules, eye drops, ear drops, ointments, creams and gels. The production areas are designed to maximize output quality and quantity with minimal down time.
The facility is WHO-GMP certified and all manufacturing areas are supplied with independent air supply systems for individual department. The independent supply systems are fed with separate air handling units to avoid cross contamination. Pressure gradients are maintained and monitored and the required air quality of class 100, 1000, 10,000 and class 100,000 is maintained.
Business area of the company
The company manufactures a wide range of products under its own brand and for a number of other reputed Indian and multinational companies. The product range includes a wide variety of ethical, generic and over the counter (OTC) drugs in various Finished Dosage Forms for both human and veterinary use.
Products
Capsules: Equipment used for the production of hard-gelatin capsules are automatic filling machine, feeder, sorter, inspection machine and polishing machine. The filled capsules are packed in high speed automatic strip and blister packing machines suitable for various sizes. The company has the ability to produce both powder filled and granule filled capsules.
Creams, Gels & Ointments: The semi-automatic machines perform the entire process of filling, sealing & crimping of the tubes in various tube sizes of Creams, Gels, Ointments, Sterile Ophthalmic Ointments and Sterile intra-mammary infusions.
Ear & Eye Drops: This department houses sophisticated machines such as automatic sealing, capping, labeling, carton forming and wrapping machines.
Injections: The parenteral is produced in a sterile area and fed to the automatic machines for ampule or vial filling, rubber bunging and cap sealing. A similar process is used for dry powder injections.
Tablets: Rapid Mixer Granulator and Fluid Bed Dryer are used to produce the material for compression in various shapes which is carried out at various multi-station, single and double rotary tablet compression machines. There are coating machines for various types of coating of the tablets. A similar process is used for boluses.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
